Patterns of bevacizumab use in patients with glioblastoma: An online survey among experts in neuro-oncology

Surabhi Ranjan, Surabhi Ranjan, Nebojša Skorupan, Xiaobu Ye, Ananyaa Sivakumar, Olga Yankulina, David Kamson, Stuart A. Grossman, Omar Dzaye, Omar Dzaye, Omar Dzaye, Matthias Holdhoff

Research output: Contribution to journalArticlepeer-review


Background: Bevacizumab (BEV) received accelerated FDA approval in 2009 for the treatment of recurrent glioblastoma (rGBM). Unfortunately, prospective randomized controlled phase 3 studies (AVAglio and Radiation Therapy Oncology Group 0825 in newly diagnosed, European Organisation for Research and Treatment of Cancer 26101 in rGBM) failed to show an overall survival benefit with BEV added to standard therapy. In light of these data, we aimed to capture current utilization patterns and perceived value of BEV in the treatment of GBM among experts in the field. Methods: An online questionnaire comprising 14 multiple choice questions was sent out in spring 2017 to 207 oncologists/neuro-oncologists treating patients with GBM at all National Cancer Institute-designated cancer centers in the United States. Results: Sixty-two of 207 (30%) invitees responded (by training, 70% neuro-oncologists, 20% medical oncologists, 10% pediatric oncologists/neuro-oncologists). Participants reported use of BEV most frequently in rGBM for control of edema (85% of respondents) and/or when no other treatment options were available (68%). BEV is rarely used in newly diagnosed GBM (<5% of cases by 78% respondents and in 5% to 10% cases by 15% respondents). Sixty-six percent of participants indicated that they thought BEV improved symptoms, 30% that it improved symptoms and survival, 3% that it had no benefit in GBM patients. Conclusion: In this cross-sectional online survey we found that among neuro-oncology experts in the United States in 2017, BEV is predominantly utilized in select patients with rGBM, and is only rarely used in a small subgroup of patients with newly diagnosed GBM for control of edema. The low response rate may have introduced a nonresponse bias.

Original languageEnglish (US)
Pages (from-to)52-58
Number of pages7
JournalNeuro-Oncology Practice
Issue number1
StatePublished - Jan 31 2020


  • bevacizumab
  • clinical practice
  • glioblastoma
  • recurrent
  • survey

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Oncology
  • Neurology


Dive into the research topics of 'Patterns of bevacizumab use in patients with glioblastoma: An online survey among experts in neuro-oncology'. Together they form a unique fingerprint.

Cite this